Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion

Boston Scientific Acquires BTG plc

August 19, 2019

Medical Devices

Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.

GSK to Acquire Sierra Oncology for $1.9 Billion

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has entered into an agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. for $1.9 billion (approximately $55 per share in cash). The acquisition is intended to bring Sierra’s lead asset momelotinib—an investigational targeted therapy for myelofibrosis and anemia—into GSK’s specialty medicines portfolio.

Amgen Acquires Dark Blue Therapeutics

January 6, 2026

Biotechnology

Amgen has acquired Dark Blue Therapeutics, an Oxford-based biotechnology company focused on targeted protein degraders for oncology, in a deal valued at up to $840 million including upfront and milestone payments. The acquisition adds Dark Blue's preclinical MLLT1/3 degrader program (DBT-3757) to Amgen's early oncology discovery efforts and will be integrated into Amgen's existing R&D organization.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Pharmaceuticals

Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.

Global Cord Blood Corporation Acquires Cellenkos, Inc.

April 29, 2022

Biotechnology

Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.

Jazz Pharmaceuticals Acquires GW Pharmaceuticals for $7.2 billion

February 3, 2021

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire GW Pharmaceuticals plc for $220 per ADS (comprised of $200 cash and $20 in Jazz ordinary shares), implying total consideration of approximately $7.2 billion ($6.7 billion net of GW cash). The boards of both companies approved the transaction, which is expected to close in Q2 2021 subject to GW shareholder approval, court sanction and customary regulatory clearances; the combined company will strengthen Jazz's neuroscience portfolio and global commercial footprint.